Fintel reports that on October 20, 2025, Needham reiterated coverage of Moderna (NasdaqGS:MRNA) with a Hold recommendation.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large ...
Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Moderna (NasdaqGS:MRNA) with a Equal-Weight ...
Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...
U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close ...
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is the kind of company that keeps ...
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will deliver an overview of the Company in a Fireside Chat hosted by ...
Cidara’s lead candidate, CD388, is a long-acting antiviral prophylactic designed for universal prevention of seasonal and ...
The Dow Jones Industrial Average clocked its fastest 10,000 point run up to cross 30,000 for the first time on Tuesday, giving the stock market a psychological boost at a time when the coronavirus ...
Indian equity markets posted slight gains in Samvat 2081, with Nifty 50 up 3.6% and Sensex 2.8% from Diwali 2024 to October ...
Nvidia share price hit a new all-time high on Tuesday, rising nearly 3 per cent and pushing the chipmaker’s market value above $4.5 trillion. Nvidia share price ended at $186.58 on September 30, ...
New Scientist on MSN
Why the next generation of mRNA vaccines is set to be even better
RNA vaccines are quick and easy to make, while virus-like nanoparticles produce a stronger immune response. Now, the two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback